Combining network pharmacology, molecular docking, molecular dynamics simulation, and experimental verification to examine the efficacy and immunoregulation mechanism of FHB granules on vitiligo

Xiaolong Li, Fengze Miao, Rujuan Xin, Zongguang Tai, Huijun Pan, Hao Huang, Junxia Yu, Zhongjian Chen, Quangang ZhuFrontiers in Immunology 2023 · DOI

Abstract

Fufang Honghua Buji (FHB) granules exert anti-inflammatory and melanogenesis-promoting effects via a multi-component, multi-target mechanism. This study identifies the JAK-STAT signaling pathway as a primary target for FHB in treating vitiligo, providing new insights into the development of traditional Chinese medicine (TCM) therapies for skin depigmentation disorders.

Introduction

Vitiligo is a chronic skin condition characterized by the selective destruction of melanocytes, resulting in white patches on the skin. Driven by complex interactions between immune dysregulation and oxidative stress, it remains a challenge to treat effectively. While conventional therapies like UV radiation and corticosteroids are common, they often carry risks of recurrence and long-term side effects such as skin atrophy.

In clinical practice, FHB granules—a 17-herb TCM formula—have demonstrated significant efficacy. However, the molecular mechanisms underlying its success have remained a "black box" due to the chemical complexity of the mixture. This research aims to bridge this gap by identifying the active compounds in FHB and their precise biological targets.

Methodology: A Hybrid Computational and Experimental Pipeline

To decode the therapeutic mechanism of FHB, researchers employed a multi-step workflow combining in silico predictions with in vivo and in vitro validation.

Figure 1: Workflow of network pharmacology, molecular docking, molecular dynamics simulation, and experimental verification for FHB granules.
  1. Network Pharmacology: Active compounds from FHB’s 17 herbs were identified using databases like TCMSP and HERB, then mapped against vitiligo-related genetic targets from OMIM and DrugBank to create a "component-target-disease" network.
  2. Molecular Docking & Dynamics (MD): The binding stability between top compounds and predicted protein targets was tested using AutoDock and GROMACS simulations (30ns) to calculate binding free energies.
  3. Experimental Validation: The team used hydroquinone (HQ) to induce vitiligo in mice and hydrogen peroxide (H2O2) to stress B16 melanoma cells. They measured melanin recovery, cytokine levels (IL-6, TNF-α), and the expression of JAK-STAT pathway components.
  4. Biosafety Screening: A 14-day toxicity study evaluated blood panels and organ histology in mice to ensure the formula's safety.

Key Insights: The "Big Three" and the STAT3 Linchpin

The study revealed that FHB's strength lies in its multi-target approach. Unlike single-target Western drugs, FHB provides a synergistic effect by suppressing inflammation while simultaneously promoting pigment production.

  • Core Compounds: Out of 291 components, three flavonoids—luteolin, wogonin, and quercetin—emerged as the primary drivers of FHB's efficacy. These molecules showed the highest connectivity to disease pathways.
  • Targeting STAT3: Computational models identified STAT3, a key transcription factor in the JAK-STAT inflammatory pathway, as the central target. MD simulations confirmed that quercetin and luteolin dock deeply into the STAT3 protein pocket, effectively blocking the phosphorylation cascade that triggers melanocyte destruction.

Experimental Results and Validation

The experimental phase confirmed the computational predictions, showing significant phenotypic and molecular improvements in treated models.

Figure 2: Experimental validation results including mouse depigmentation scores, cytokine levels (ELISA/IHC), and JAK-STAT pathway expression (qRT-PCR/WB).
  • Phenotypic Rescue: High-dose FHB (7.2g/kg) significantly reduced depigmentation areas in mice and restored melanin granules within hair follicles.
  • Pathway Suppression: FHB treatment led to a drastic reduction in inflammatory cytokines (IL-6 and TNF-α). Crucially, Western blot and qRT-PCR analysis showed that FHB suppressed the mRNA and protein expression of the entire JAK-STAT cascade (Jak1/2 and Stat1/2/3).
  • Binding Affinity: MD simulations showed that STAT3-quercetin had the most stable interaction, with a remarkably low binding free energy of -94.260 KJ/mol.
  • Safety Profile: The 14-day toxicity test resulted in 100% survival with no signs of liver or kidney toxicity, confirming the formula's high biosafety for clinical use.

Conclusion and Future Directions

This study successfully demystifies the mechanism of FHB granules, highlighting the JAK-STAT pathway as a validated target for vitiligo therapy. While the results are promising, the authors note that network pharmacology is limited by the completeness of existing databases. Furthermore, while the "Big Three" compounds are critical, the full therapeutic effect likely relies on the synergy of the entire 17-herb formula. Future research will explore other predicted pathways, such as NF-κB and PI3K/Akt, to fully map the multi-dimensional impact of FHB on skin health.

Summary updated

Abstract

FHB exerts anti-inflammatory and melanogenesis-promoting effects via the effect of multi-component on multi-target, among which the JAK-STAT pathway is a validated FHB-vitiligo target, providing new ideas and clues for the development of vitiligo therapy.
BibTeX
@inproceedings{li2023combining,
  author = {Xiaolong Li and Fengze Miao and Rujuan Xin and Zongguang Tai and Huijun Pan and Hao Huang and Junxia Yu and Zhongjian Chen and Quangang Zhu},
  title = {{Combining network pharmacology, molecular docking, molecular dynamics simulation, and experimental verification to examine the efficacy and immunoregulation mechanism of FHB granules on vitiligo}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1194823},
}
Figure